| 注册
首页|期刊导航|国际眼科杂志|康柏西普治疗慢性中心性浆液性脉络膜视网膜病变的疗效

康柏西普治疗慢性中心性浆液性脉络膜视网膜病变的疗效

姚亮 吕莎莎 刘子瑶 冯海晓 郑玉萍 王建明 王峰

国际眼科杂志2017,Vol.17Issue(6):1139-1142,4.
国际眼科杂志2017,Vol.17Issue(6):1139-1142,4.

康柏西普治疗慢性中心性浆液性脉络膜视网膜病变的疗效

Observation on the efficacy of Conbercept for chronic central serous chorioretinopathy

姚亮 1吕莎莎 1刘子瑶 1冯海晓 1郑玉萍 1王建明 1王峰1

作者信息

  • 1. 710004 中国陕西省西安市,西安交通大学第二附属医院眼科
  • 折叠

摘要

Abstract

AIM:To observe the efficacy of intravitreal conbercept injection for chronic central serous chorioretinopathy (CSC).METHODS: Nine eyes of 9 patients diagnosed as chronic CSC between October 2015 to May 2016 were treated with an intravitreal injection of conbercept (0.5mg/0.05mL) (six patients were given the same does of intravitreal injection again at 1mo after the first injection).Follow-up observation was at 1, 2, and 6mo after injection.Observed indicators included best-corrected visual acuity (BCVA), intraocular pressure, optical coherence tomography (OCT), fundus fluorescein angiography (FFA), choroidal indocyanine green angiography (ICGA), macular fovea thickness (CMT), subfoveal choroidal thickness (SFCT).RESULTS:Seven of the 9 patients responded significantly to the drug, while 2 patients had no response.The CMT was 373.12±72.43μm at baseline, which decreased significantly to 332.05±67.13μm, 282.24±62.30μm and 225.56±71.08μm at 1, 2 and 6mo after the intravitreal injection.The mean thickness of SFCT was 422.11±64.82μm before treatment.The choroidal thickness of non-responsive patients before treatment was below average, respectively 353μm and 365μm.The SFCT of 1, 2, and 6mo after treatment was 391.45±75.24μm, 365.53±63.07μm, 355.40±66.65μm.Before treatment and 1mo after, there was no significant difference (P=0.074), but there was statistically significant (P<0.01) between those of before and 2mo and 6mo after.The mean BCVA of the prior treatment was 0.53±0.32, the after treatment was 0.65±0.20, there was no different between the two(P>0.05).CONCLUSION: Intravitreal conbercept injection in chronic CSC may have some effect in accelerating subertinal fluid resolution and decreasing the CMT.The SFCT within 6mo after treatment was significantly lower than pretreatment.The SFCT may be an indicator of whether patients respond.

关键词

康柏西普/慢性中心性浆液性脉络膜视网膜病变/玻璃体腔注射

Key words

conbercept/chronic central serous chorioretinopathy/intravitreal injection

引用本文复制引用

姚亮,吕莎莎,刘子瑶,冯海晓,郑玉萍,王建明,王峰..康柏西普治疗慢性中心性浆液性脉络膜视网膜病变的疗效[J].国际眼科杂志,2017,17(6):1139-1142,4.

基金项目

国家自然科学基金资助项目(No.81601222)National Natural Science Foundation of China (No.81601222) (No.81601222)

国际眼科杂志

OA北大核心CSTPCD

1672-5123

访问量1
|
下载量0
段落导航相关论文